Investor Alert

Dow Jones Newswires Archives | Email alerts

Dec. 9, 2019, 4:08 a.m. EST

Sanofi to acquire Synthorx for $2.5 billion

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Sanofi S.A. (SAN)
  • X
    Sanofi ADR (SNY)

or Cancel Already have a watchlist? Log In

By Kim Richters

AFP via Getty Images
The logo of French multinational pharmaceutical company Sanofi is pictured on a screen on December 4, 2017 at the company's Val de Bievre Campus, at its headquarters in Gentilly, near Paris.

Sanofi SA said Monday that it will acquire biotechnology company Synthorx Inc. for an aggregated equity value of around $2.5 billion.

The French pharmaceutical company /zigman2/quotes/206928357/delayed FR:SAN -1.30%   /zigman2/quotes/201967021/composite SNY -1.95%  said it plans to take control of all outstanding shares of Synthorx  for $68 per share in cash.

The acquisition of Synthorx, which is expected to close in the first quarter next year, will strengthen Sanofi’s existing immuno-oncology portfolio, it said.

The takeover is “aligned with our goal to build our oncology franchise with potentially practice-changing medicines and novel combinations,” Sanofi’s Chief Executive Paul Hudson said.

FR : France: Euronext Paris
-1.12 -1.30%
Volume: 2.11M
Sept. 22, 2020 5:36p
P/E Ratio
Dividend Yield
Market Cap
€107.90 billion
Rev. per Employee
US : U.S.: Nasdaq
$ 49.86
-0.99 -1.95%
Volume: 1.01M
Sept. 22, 2020 4:00p
P/E Ratio
Dividend Yield
Market Cap
$126.70 billion
Rev. per Employee

Get news alerts on Sanofi ADR — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.